129 related articles for article (PubMed ID: 24552605)
1. Diabetes and immune thrombocytopenic purpura: a new association with good response to anti-CD20 therapy.
von Laer Tschudin L; Schwitzgebel VM; von Scheven-Gête A; Blouin JL; Hofer M; Hauschild M; Ansari M; Stoppa-Vaucher S; Phan-Hug F
Pediatr Diabetes; 2015 Mar; 16(2):138-45. PubMed ID: 24552605
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus.
Lee JW; Kim HA; Sung JM; Suh CH
Lupus; 2010 Feb; 19(2):227-8. PubMed ID: 19884220
[No Abstract] [Full Text] [Related]
4. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
5. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
[TBL] [Abstract][Full Text] [Related]
6. Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.
Liebman HA; Saleh MN; Bussel JB; Negrea OG; Horne H; Wegener WA; Goldenberg DM
Br J Haematol; 2013 Sep; 162(5):693-701. PubMed ID: 23829485
[TBL] [Abstract][Full Text] [Related]
7. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
Latifzadeh SZ; Entezari V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
[TBL] [Abstract][Full Text] [Related]
8. [Idiopathic thrombocytopenic purpura in children].
Gebauer E; Vijatov G
Med Pregl; 1998; 51(3-4):127-34. PubMed ID: 9611955
[TBL] [Abstract][Full Text] [Related]
9. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
11. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
12. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
13. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
14. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
15. Negativation of type 1 diabetes-associated autoantibodies to glutamic acid decarboxylase and insulin in children treated with oral calcitriol.
Papadimitriou DT; Marakaki C; Fretzayas A; Nicolaidou P; Papadimitriou A
J Diabetes; 2013 Sep; 5(3):344-8. PubMed ID: 23302101
[TBL] [Abstract][Full Text] [Related]
16. Is B-cell depletion still a good strategy for treating immune thrombocytopenia?
Godeau B; Stasi R
Presse Med; 2014 Apr; 43(4 Pt 2):e79-85. PubMed ID: 24636845
[TBL] [Abstract][Full Text] [Related]
17. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
Bengtson KL; Skinner MA; Ware RE
J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of a patient with mixed warm and cold antibody mediated Evans syndrome and glucose intolerance.
Jubinsky PT; Rashid N
Pediatr Blood Cancer; 2005 Sep; 45(3):347-50. PubMed ID: 15704210
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura.
Delgado J; Bustos JG; Jimenez-Yuste V; Hernandez-Navarro F
Haematologica; 2002 Feb; 87(2):215-6. PubMed ID: 11836172
[TBL] [Abstract][Full Text] [Related]
20. Diabetes technology and treatments in the paediatric age group.
Shalitin S; Peter Chase H
Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
